Article

Congress Fights DIR Fees Highlights SPT Week in Review

Author(s):

Top news of the week from Specialty Pharmacy Times.

5. Transcranial Direct Current Stimulation Reduces Fatigue in Multiple Sclerosis

An estimated 75% of patients with multiple sclerosis report fatigue among their most disabling disease symptoms. Read more.

4. Adherence in a Nutshell

Non-adherence to medication regimens is estimated to cost approximately $290 billion dollars in unnecessary medical expenses. Read more.

3. Independent Oncology Practices Could Lower Health Care Costs

Cancer care at hospitals is significantly more expensive than at community oncology clinics. Read more.

2. Specialty Pharmacies Poised to Connect Ovarian Cancer Patients with Crucial Services

Patients with ovarian cancer often face complex burdens that go beyond just medication. Read more.

1. Congress Urges HHS, CMS to Terminate DIR Fees

Legislators are becoming more informed about DIR fees and their harms on Medicare beneficiaries and specialty pharmacies. Read more.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards